Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKesson
Medtronic
AstraZeneca
McKinsey
Merck
Moodys

Last Updated: October 24, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for AZD-7762

See Plans and Pricing

« Back to Dashboard

Development status for investigational drug AZD-7762: Sponsors, patents, clinical trial progress

AZD-7762 is an investigational drug.

There have been 30 clinical trials for AZD-7762. The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2010.

The most common disease conditions in clinical trials are Ovarian Neoplasms, Small Cell Lung Carcinoma, and Lung Neoplasms. The leading clinical trial sponsors are AstraZeneca, National Cancer Institute (NCI), and Samsung Medical Center.

There are fifteen US patents protecting this investigational drug and one hundred and fifty international patents.

Recent Clinical Trials for AZD-7762
TitleSponsorPhase
Adavosertib With or Without Olaparib in Treating Participants With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube CancerNational Cancer Institute (NCI)Phase 2
Adavosertib With or Without Olaparib in Treating Participants With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube CancerM.D. Anderson Cancer CenterPhase 2
Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian CancerAstraZenecaPhase 2

See all AZD-7762 clinical trials

Clinical Trial Summary for AZD-7762

Top disease conditions for AZD-7762
Top clinical trial sponsors for AZD-7762

See all AZD-7762 clinical trials

US Patents for AZD-7762

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
AZD-7762   Start Trial Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines Signal Pharmaceuticals, LLC (San Diego, CA)   Start Trial
AZD-7762   Start Trial Antibody drug conjugates Novartis AG (Basel, CH)   Start Trial
AZD-7762   Start Trial Antibody drug conjugates Novartis AG (Basel, CH)   Start Trial
AZD-7762   Start Trial Formylated N-heterocyclic derivatives as FGFR4 inhibitors NOVARTIS AG (Basel, CH)   Start Trial
AZD-7762   Start Trial Methods and compositions for treatment of cancer and autoimmune disease THE JACKSON LABORATORY (Bar Harbor, ME)   Start Trial
AZD-7762   Start Trial Triazolopyrimidine compounds and uses thereof Novartis AG (Basel, CH)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for AZD-7762

Drugname Country Document Number Estimated Expiration Related US Patent
AZD-7762 European Patent Office 3131552 2034-04-16   Start Trial
AZD-7762 Japan 2017514806 2034-04-16   Start Trial
AZD-7762 Japan 2019070012 2034-04-16   Start Trial
AZD-7762 New Zealand 629860 2034-04-16   Start Trial
AZD-7762 World Intellectual Property Organization (WIPO) 2015160868 2034-04-16   Start Trial
AZD-7762 Argentina 102649 2034-11-14   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Harvard Business School
Moodys
Colorcon
Dow
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.